Analysis: Biotech's resistance to generics might be valid

03/3/2004 | Wall Street Journal, The

Biotech officials often point to the case of problems resulting from a generic version of Johnson & Johnson's Eprex drug as evidence problems can arise from allowing cheaper versions of biotech drugs. Unlike most drugs, these medicines use bioengineered cells, which can produce different results upon duplication. Generic drug makers say they recognize the problem and are looking for safe ways to copy biotech drugs and reduce the approval process. The FDA is also drafting scientific guidelines to address this issue.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX